# Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma

> **NCT03608618** · PHASE1 · TERMINATED · sponsor: **MaxCyte, Inc.** · enrollment: 14 (actual)

## Conditions studied

- Peritoneal Mesothelioma
- Fallopian Tube Adenocarcinoma
- Adenocarcinoma of the Ovary
- Primary Peritoneal Carcinoma

## Interventions

- **BIOLOGICAL:** MCY-M11
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT03608618
- **Lead sponsor:** MaxCyte, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-27
- **Primary completion:** 2021-02-11
- **Final completion:** 2021-08-24
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Sponsor shift in focus
- **Last updated:** 2021-09-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03608618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03608618, "Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03608618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*